Market Access Biotech funding has returned. The bar has moved with it. For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Market Access Capital discipline in biotech: Building enduring companies w... Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.
R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
Sales & Marketing A fast start to 2026 signals continued investor confidence i... Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.
Market Access Capital efficient trials in a time of economic uncertainty In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, pharma and biotech companies should address not just whether a trial
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.